Kakkis Emil D

Kakkis Emil D is listed in filings as President & CEO at Ultragenyx Pharmaceutical Inc. This profile follows SEC Form 4 activity through Apr 20, 2026, including sale activity. Recent filings connect the profile to Ultragenyx Pharmaceutical Inc (RARE). The current snapshot covers public activity from Aug 7, 2024 to Apr 20, 2026. Reported amounts are shown as $1.0M to $413.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.